Stocks › OCGN
Ocugen, Inc.
OCGN·Nasdaq·
United States·USD
United States·USD$1.04
+0.00 (+0.00%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
OCGN
Ocugen, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
OCGNS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of OCGN by members of U.S. Congress · 2 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Christopher L. JacobsHouse · R · NY |
OCGNOcugen, Inc. · Stock |
Sale $1,001 - $15,000 |
Dec 12, 2022 | Nov 8, 2022 | Filing ↗ |
| Christopher L. JacobsHouse · R · NY |
OCGNOcugen, Inc. · Stock |
Purchase $15,001 - $50,000 |
Jul 28, 2022 | Jun 16, 2022 | Filing ↗ |
Whale Activity
Position changes in OCGN reported for 2026-06-30 by 7 tracked institutional filers
- Increased4
- New0
- Held0
- Decreased3
- Closed0
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 27.0M | $41.3M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 14.4M | $22.0M | increased |
| MILLENNIUM MANAGEMENT LLC | 13.9M | $21.3M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.3M | $5.1M | increased |
| TWO SIGMA INVESTMENTS, LP | 2.2M | $3.4M | decreased |
| CITADEL ADVISORS LLC | 783.3K | $1.2M | decreased |
| Point72 Asset Management, L.P. | 477.8K | $731K | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by OCGN insiders, by quarter · Form 4
Recent Insider Transactions
172 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Musunuri ShankarChief Executive Officer · Director | Sale | −57.3K | $1.12 | $64K | Sep 9, 2026 | Form 4 ↗ |
| Musunuri ShankarChief Executive Officer · Director | Sale | −468.7K | $1.12 | $525K | Sep 9, 2026 | Form 4 ↗ |
| Johnson-Greene Treerita EssalimaChief Financial Officer | Purchase | +21.0K | $1.23 | $26K | Jun 15, 2026 | Form 4 ↗ |
| Zhang JungeDirector | Option exercise | +66.9K | $1.42 | $95K | Apr 1, 2026 | Form 4 ↗ |
| Zhang JungeDirector | Option exercise | +112.2K | $0.46 | $52K | Apr 1, 2026 | Form 4 ↗ |
| Zhang JungeDirector | Option exercise | +15.0K | $0.51 | $8K | Apr 1, 2026 | Form 4 ↗ |
| Musunuri ShankarChief Executive Officer · Director | Grant / award | +3.1M | $0.00 | $0 | Jan 2, 2026 | Form 4 ↗ |
| Ramachandran RameshChief Accounting Officer | Grant / award | +207.3K | $0.00 | $0 | Jan 2, 2026 | Form 4 ↗ |
| Upadhyay ArunSee Remarks | Tax withholding | −41.6K | $0.89 | $37K | Jan 3, 2025 | Form 4 ↗ |
| Musunuri ShankarChief Executive Officer · Director | Tax withholding | −177.1K | $0.89 | $158K | Jan 3, 2025 | Form 4 ↗ |
| Fernandes PrabhavathiDirector | Purchase | +10.0K | $0.91 | $9K | Nov 26, 2024 | Form 4 ↗ |
| Castillo KirstenDirector | Purchase | +25.0K | $0.91 | $23K | Nov 22, 2024 | Form 4 ↗ |
| Upadhyay ArunSee Remarks | Tax withholding | −842 | $1.17 | $985 | Sep 16, 2024 | Form 4 ↗ |
| Upadhyay ArunSee Remarks | Tax withholding | −917 | $1.42 | $1K | Jun 17, 2024 | Form 4 ↗ |
| Musunuri ShankarChief Executive Officer · Director | Tax withholding | −180.2K | $0.65 | $117K | Jan 3, 2024 | Form 4 ↗ |
| Upadhyay ArunSee Remarks | Tax withholding | −41.6K | $0.65 | $27K | Jan 3, 2024 | Form 4 ↗ |
| Upadhyay ArunSee Remarks | Tax withholding | −842 | $0.41 | $345 | Sep 16, 2023 | Form 4 ↗ |
| Upadhyay ArunChief Scientific Officer | Tax withholding | −917 | $0.51 | $468 | Jun 16, 2023 | Form 4 ↗ |
| Zhang JungeDirector | Purchase | +200.3K | $0.50 | $100K | Jun 14, 2023 | Form 4 ↗ |
| Musunuri ShankarChief Executive Officer · Director | Sale | −100.0K | $1.08 | $108K | Feb 16, 2023 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding OCGN · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 14.0M | $21.4M | 0.20% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 10.2M | $15.6M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 8.7M | $13.3M | 0.02% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.9M | $5.9M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 3.7M | $4.6M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 2.2M | $3.4M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF SPDR SERIES TRUST | 1.8M | $2.8M | 0.10% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 1.7M | $2.4M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF iShares Trust | 1.1M | $1.8M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 996.7K | $1.5M | 0.01% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list OCGN's shares (CUSIP 67577C105), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming ocugen as client
Government Contracts
Federal awards to Ocugen, Inc. · USAspending
No federal contract awards found for Ocugen, Inc..
U.S. Patents
Recent USPTO applications naming Ocugen, Inc.
No USPTO patent applications found for Ocugen, Inc..
Annual Financials
From OCGN's 10-K filings · XBRL
No annual XBRL figures on record for OCGN. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-60Reverse splitSep 30, 2019
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.07Shareholder voteSep 23, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 13, 2026
EDGAR ↗ - 8-K · Items 5.07, 8.01Shareholder vote · Other eventsJun 11, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeJun 3, 2026
EDGAR ↗ - 8-K · Items 5.02, 8.01Officer / director change · Other eventsMay 14, 2026
EDGAR ↗ - 8-K · Items 2.03, 3.02, 7.01, 9.01Direct financial obligation · Unregistered sale of equity · Reg FD disclosureMay 14, 2026
EDGAR ↗ - 8-K · Items 1.01, 1.02, 2.02, 2.03, 3.02, 9.01Material agreement · Termination of agreement · Results of operationsMay 7, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsMay 5, 2026
EDGAR ↗
About Ocugen, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersMALVERN, PA
IncorporatedDE
SEC CIK0001372299 ↗
Former namesHISTOGENICS CORP